| Name | Valsartan |
| Description | Valsartan (CGP 48933) is a tetrazole derivative and angiotensin II type 1 receptor blocker that is used to treat hypertension. |
| In vitro | Valsartan is a potent diuretic, ACE inhibitor, calcium antagonist, and β-blocker.Valsartan dose-dependently inhibited vasoconstriction of angiotensin II-induced vasoconstriction and lowered blood pressure in a renin-dependent model of hypertension. |
| In vivo | Valsartan is a potent diuretic, ACE inhibitor, calcium antagonist, and β-blocker.Valsartan dose-dependently inhibited vasoconstriction of angiotensin II-induced vasoconstriction and lowered blood pressure in a renin-dependent model of hypertension. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 2 mg/mL (4.59 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 250 mg/mL (574.03 mM), Sonication is recommended.
|
| Keywords | Valsartan | TLR2 | proinflammatory | pressure | Inhibitor | inhibit | heart | failure | endothelial | cytokines | CGP-48933 | CGP48933 | blood | aorta | Angiotensin Receptor | angiotensin II receptor |
| Inhibitors Related | Losartan potassium | Tranilast | Enalapril Maleate | Telmisartan | Lisinopril dihydrate | Sacubitril/Valsartan | Benzyl benzoate | Irbesartan | Losartan | Ramipril | Diisononyl phthalate | Captopril |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Endocrinology-Hormone Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |